Breaking News, Collaborations & Alliances

Menlo Therapeutics Signs Exclusive License Agreement

Partners with Japan Tobacco and Torii Pharma for development and commercialization of NK-1 receptor antagonist in Japan

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Menlo Therapeutics has entered into an exclusive license agreement with Japan Tobacco and Torii Pharmaceutical for the development and commercialization of serlopitant in Japan. Serlopitant is a first–in-class, once-daily oral NK-1 receptor antagonist candidate for the treatment of pruritus. Serlopitant has demonstrated antipruritic effects in a Phase 2 clinical trial in patients with severe, chronic pruritus conducted by Menlo Therapeutics. Japan Tobacco and Torii will jointly develop serlop...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters